The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1453-1462

  You, Feng ^a   Hu, Jinping ^a   Li, Xue ^a   Li, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Caco 2 cell; Elimination; Liver perfusion; MTC 220; Transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DRUG METABOLITE; MTC 220; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MURAMYL DIPEPTIDE DERIVATIVE; NOVOBIOCIN; ORGANIC ANION TRANSPORTING POLYPEPTIDE; PACLITAXEL DERIVATIVE; PROBENECID; RIFAMPICIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG URINE LEVEL; LIVER MICROSOME; LIVER PERFUSION; MALE; MONOLAYER CULTURE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; BILE; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DIPEPTIDES; DRUG INTERACTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84878647377     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2144-7     Document Type: Article

References (45)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325-2327
2. Ferlini C, Gallo D, Scambia G (2008) New taxanes in development. Expert Opin Investig Drugs 17(3):335-347
3. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M (2001) Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 7(3):232-236
4. Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248(4953):370-372
5. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457(7225):102-106
6. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25(3):409-416
7. Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59(4):1317-1325
8. Adam A, Ciorbaru R, Ellouz F, Petit JF, Lederer E (1974) Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem Biophys Res Commun 56(3):561-567
9. Parant MA, Audibert FM, Chedid LA, Level MR, Lefrancier PL, Choay JP, Lederer E (1980) Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs. Infect Immun 27(3):826-831
10. Riveau GJ, Brunel-Riveau BG, Audibert FM, Chedid LA (1991) Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens. Cell Immunol 134(1):147-156
11. MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J et al (1994) Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target 2(5):391-396
12. Yoo YC, Saiki I, Sato K, Azuma I (1994) MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice. Vaccine 12(2):175-180
13. Mori K, Ando K, Heymann D (2008) Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther 8(2):151-159
14. Ma Y, Zhao N, Liu G (2011) Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice. J Med Chem 54(8):2767-2777
15. Funk C (2008) The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4(4):363-379
16. Hinchman CA, Rebbeor JF, Ballatori N (1998) Efficient hepatic uptake and concentrative biliary excretion of a mercapturic acid. Am J Physiol 275(4 Pt 1):G612-G619
17. Zheng Y, Yang XW (2008) Absorption and transport of pachymic acid in the human intestinal cell line Caco-2 monolayers. Zhong Xi Yi Jie He Xue Bao 6(7):704-710
18. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL (2005) Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos 33(8):1158-1165
19. Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K (2010) Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters. Drug Metab Pharmacokinet 25(4):320-327
20. Zhao D, Gao ZD, Han DE, Li N, Zhang YJ, Lu Y, Li TT, Chen XJ (2012) Influence of rifampicin on the pharmacokinetics of salvianolic acid B may involve inhibition of organic anion transporting polypeptide (Oatp) mediated influx. Phytother Res 26(1):118-121
21. Su Y, Hu P, Lee SH, Sinko PJ (2007) Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharm Sci 10(4):519-536
22. Yanxiao C, Ruijuan X, Jin Y, Lei C, Qian W, Xuefen Y, Hong T, Xueying Z, Davey AK, Jiping W (2011) Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 89(1-2):1-6
23. Shin YJ, Lee JH, Oh JH, Lee YJ (2011) Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion. J Appl Toxicol. (Epub ahead of print). doi: 10.1002/jat.1778
24. Liu Y, He J, Abliz Z, Zhu H (2011) In vitro stability and metabolism of O2′, O3′, O5′-tri-acetyl-N6-(3-hydroxylaniline) adenosine in rat, dog and human plasma: chemical hydrolysis and role of plasma esterases. Xenobiotica 41(7):549-560
25. Zhao B, Yang XB, Yang XW, Wu Q, Wang Y, Zhang LX, Xu W (2011) Intestinal permeability of the constituents from the roots of saposhnikovia divaricata in the human Caco-2 cell monolayer model. Planta Med 77(13):1531-1535
26. Kim MK, Shim CK (2006) The transport of organic cations in the small intestine: current knowledge and emerging concepts. Arch Pharm Res 29(7):605-616
27. Dahan A, Amidon GL (2009) Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 297(2):G371-G377
28. Ovadia O, Greenberg S, Chatterjee J, Laufer B, Opperer F, Kessler H, Gilon C, Hoffman A (2011) The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm 8(2):479-487
29. Foltz M, van Buren L, Klaffke W, Duchateau GS (2009) Modeling of the relationship between dipeptide structure and dipeptide stability, permeability, and ACE inhibitory activity. J Food Sci 74(7):H243-H251
30. ShimXizu K, Sato M, Zhang Y, Kouguchi T, Takahata Y, Morimatsu F, Shimizu M (2010) Molecular size of collagen peptide reverses the permeability of Caco-2 cells. Biosci Biotechnol Biochem 74(5):1123-1125
31. Yamamoto A (1998) Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids. Nihon Rinsho 56(3):601-607
32. Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, Morgan P, Barton HA (2012) The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 42(1):28-45
33. Ninomiya M, Ito K, Horie T (2005) Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab Dispos 33(2):225-232
34. Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL (2003) Pharmacokinetics of 5 (and 6)-carboxy-2′,7′- dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304(2):801-809
35. Bailey DG, Dresser GK, Leake BF, Kim RB (2007) Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 81(4):495-502
36. Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL, Giacomini KM, Artursson P (2011) Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 11(6):400-411
37. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, Inui K (2009) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329(1):185-191
38. Duan P, You G (2009) Novobiocin is a potent inhibitor for human organic anion transporters. Drug Metab Dispos 37(6):1203-1210
39. Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL (2007) Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob Agents Chemother 51(9):3230-3234
40. Bahar FG, Ohura K, Ogihara T, Imai T (2012) Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101(10):3979-3988
41. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H (2009) In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 39(5):391-398
42. Vaclavikova R, Horsky S, Simek P, Gut I (2003) Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 368(3):200-209
43. Steed H, Sawyer MB (2007) Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8(7):803-815
44. Gao Y, Liu D, Wang H, Zhu J, Chen C (2010) Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 40(7):467-475
45. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37(2):386-390